1 completed, 1 withdrawn. 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 2 | Completed 1, Withdrawn 1 |
Follow Velcade: new trials by email Literature Review of Velcade trials Research Report on Velcade
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies Bortezomib, Busulfan, Cyclophosphamide - Beta Thalassemia Major, Sickle Beta 0 Thalassemia | Early Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2020-12-29 | 2024-10-24 | |
| A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma bortezomib and G-CSF - Malignant Lymphoma, Stem Cell Type, Autologous Transplant | Early Phase 1 | Completed | University of Kansas Medical Center | 21 | 2010-09-01 | 2017-01-11 |
Anemia, Sickle Cell (1) · Lymphoma (1) · Neoplasms, Plasma Cell (1) · beta-Thalassemia (1)
M.D. Anderson Cancer Center (1) · University of Kansas Medical Center (1)
United States (1)
Kris M Mahadeo (1) · Sunil Abhyankar, MD (1)